APC News
Lilly intervenes in OFA lawsuit against FDA
Lilly says the FDA isn’t allowed to decide when compounders can compound FDA-approved drugs.
January 10, 2025
Reason #1 to come to the APC Owner Summit
"Turning Science into Stories" with Andrew Buck will teach you how to turn facts into stories that will connect with both rational and emotional audiences.
January 10, 2025
FDA releases final interim guidance on bulk drug substances for both 503As and 503Bs
This new guidance supersedes the 2017 versions of the same titles.
January 10, 2025
Why you need to sign up for an APC Package Deal — and why now is the right time
The beginning of the calendar year is the best time to be grab a package deal.
January 10, 2025
FDA doubles down: Tirzepatide is off shortage
...but that doesn't mean the issue is completely settled.
December 20, 2024
Earlier news
December 20, 2024
Thumbs-up for FDA crackdown
APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds.
December 20, 2024
A PANS/PANDAS explainer
For your patients: Information about a couple of underdiagnosed pediatric mental health conditions
December 20, 2024
What, a year?
In the final board chair column of the year, here are our top 7 accomplishments in 2024.
December 13, 2024
“Simply not a rational approach to regulating an industry”
This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations.
December 13, 2024
Get a cease and desist letter from Verrica?
APC has heard reports from several pharmacies that have received them — here's what to know.
December 12, 2024
PCF awards state association CE grants
The Pharmacy Compounding Foundation has awarded $1,500 grants to eight state pharmacy associations.
December 6, 2024
Compounding vs. counterfeit — ABC News gets it
When ABC News wanted to do a story on compounded GLP-1s, it turned to APC. Of course.
December 6, 2024
No no, Novo!
Novo Nordisk asked the FDA to put semaglutide on the Demonstrably Difficult to Compound (DDC) list, and now APC has formally responded, pulling exactly zero punches.
December 6, 2024
About that Diabetes Association statement …
The American Diabetes Association gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk.
December 6, 2024
Foundation welcomes 2025 board members
Congratulations to the newest members of the Pharmacy Compounding Foundation Board of Directors
November 22, 2024
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages.
November 22, 2024
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.
